Therapies and outcomes of non-renal cell carcinoma (non-RCC) neoplasms of the kidney: A single-institution experience.

2012 ◽  
Vol 30 (5_suppl) ◽  
pp. 431-431 ◽  
Author(s):  
Marc Ryan Matrana ◽  
Priya Rao ◽  
Bradley J. Atkinson ◽  
Charles Guo ◽  
Nizar M. Tannir
Keyword(s):  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Small Cell ◽  
Carcinoid Tumors ◽  
Specific Data ◽  
Whole Brain Radiation ◽  
Neuroectodermal Tumors ◽  
Blue Cell ◽  
Brain Radiation

431 Background: Non-RCC neoplasms of the kidney include neuroendocrine tumors (small cell carcinoma and carcinoid) and Primitive Neuroectodermal Tumors (PNET). Small cell carcinoma and renal carcinoids are small blue cell tumors that rarely occur as primary renal neoplasms. PNET, known as extraskeletal Ewing sarcoma, is characterized by t(11;22), the gold standard for diagnosis. It is a small round cell tumor derived from the neural crest and treated with chemotherapy; the role of nephrectomy is unclear. Methods: We reviewed records of patients seen at MDACC between 01/01/2001 and 01/01/2011 for PNET, small cell carcinomas, and carcinoid tumors of the kidney. Overall survival (OS) was determined from diagnosis to death. Results: 21 pts met inclusion criteria. Disease-specific data is shown in the table. Common treatments included: carboplatin/etoposide for small cell carcinomas; vincristine/doxorubicin/ifosfamide, vincristine/doxorubicin/cyclophosphamide, and doxorubicin/ifosfamide alternating with cisplatin/etoposide for PNET. Irinotecan was a common salvage agent in PNET. Most carcinoid tumors were treated with surgery alone. Two patients with small cell received whole brain radiation for brain metastases. Conclusions: Carcinoid tumors of the kidney had better outcomes compared to renal small cell carcinomas or PNET. Local carcinoid tumors of the kidney were generally managed with surgery alone. Renal small cell carcinomas and PNET were treated with systemic therapies. [Table: see text]

Small cell carcinoma of the esophagus: Review of the Memorial Sloan-Kettering Cancer Center (MSKCC) experience

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 4631-4631
Author(s):  
G. Y. Ku ◽  
D. Kelsen ◽  
B. Minsky ◽  
V. Rusch ◽  
M. Bains ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Gastroesophageal Junction ◽  
Small Cell ◽  
Cancer Center ◽  
Carcinoma Of The Esophagus ◽  
Curative Therapy ◽  
Whole Brain Radiation ◽  
Optimal Approach ◽  
Brain Radiation

4631 Background: Esophageal small cell carcinoma (ESC) is rare and accounts for <1% of all esophageal cancers. It is treated like pulmonary SC but the optimal approach of surgery, chemotherapy or radiotherapy is unknown. Prior series (Chest 107:179, Cancer 88:262) indicate a poor median overall survival (OS) of 7–12 months (mos), rare long-term (LT) survival and the need for surgery as part of curative therapy. Methods: We reviewed records of patients (pts) with ESC treated from 1980 to 2005. All pathology was reviewed at MSKCC. Results: 24 pts were identified, with records available for 21. 86% male, 14% female, median age 60, 67% smokers. 81% had pure SC histology, with 85% of tumors in the lower esophagus or gastroesophageal junction. 13/21 (62%) had limited disease (LD) by VALSG criteria. For extensive disease (ED), liver (63%) was most common metastatic site (mets). Treatment for LD was: chemotherapy (chemo) only (3 pts, 23%), surgery only (1 pt, 8%), surgery and adjuvant chemo (3 pts) and chemoradiation (CRT) without surgery (6 pts, 46%). The most common chemo given was cisplatin/carboplatin and etoposide (81%). Pts with ED received chemo alone. Overall median survival was 19.8 mos (range, 1.5 mos to 11.2+ years (yrs)); for LD Pts, 22.3 mos (range, 6 mos to 11.2+ yrs); for ED Pts, 10.9 mos (range, 1.5 mos to 2.2 yrs). At median follow-up of 32 mos, 5 pts are alive (4 without disease (NED) and 1 with disease); 2 pts are alive >5 yrs. 4 originally had LD and 3 of 4 received CRT only without surgery. None received whole brain radiation (WBXRT). 1 LD pt treated with surgery and adjuvant chemo recurred after 4 yrs, was salvaged with CRT and is NED 11.2 yrs after diagnosis. Of 18 pts with progression, 10 (56%) had new mets. Most common site was liver (4 pts) and only 1 pt had brain mets. Of 6 pts with LD who received CRT only, 3 recurred (1 local and 2 distant). Of 4 pts with LD who underwent surgery, all recurred (1 local, 3 distant). Conclusions: Pts with ESC with LD who received CRT without surgery can have LT survival. The role of surgery remains unclear. LT survival for 1 pt who underwent salvage CRT for recurrence after surgery argues for aggressive therapy for recurrence. Unlike pulmonary SC, brain mets are uncommon and WBXRT may not be needed for LT survival. No significant financial relationships to disclose.

Role of surgery in the management and prognosis of limited-stage small cell carcinoma of the esophagus

2014 ◽  
Vol 28 (5) ◽  
pp. 476-482 ◽  
Author(s):  
M. R. Xie ◽  
S. B. Xu ◽  
X. H. Sun ◽  
L. Ke ◽  
X. Y. Mei ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Small Cell ◽  
Carcinoma Of The Esophagus ◽  
Limited Stage

scholarly journals The Current Role of Whole Brain Radiation Therapy in Non–Small Cell Lung Cancer Patients

2017 ◽  
Vol 12 (10) ◽  
pp. 1467-1477 ◽  
Author(s):  
Gokoulakrichenane Loganadane ◽  
Lizza Hendriks ◽  
Cécile Le Péchoux ◽  
Antonin Levy
Keyword(s):  
Lung Cancer ◽  
Radiation Therapy ◽  
Cancer Patients ◽  
Small Cell ◽  
Small Cell Lung ◽  
Current Role ◽  
Lung Cancer Patients ◽  
Whole Brain Radiation ◽  
Brain Radiation

Small Cell Carcinoma of the Lung: The Role of Surgery

CHEST Journal ◽  
2004 ◽  
Vol 126 (4) ◽  
pp. 770S
Author(s):  
Francis C. Nichols ◽  
Vidhan Chandra ◽  
Mark S. Allen ◽  
Claude Deschamps ◽  
Stephen D. Cassivi ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Small Cell

Small cell carcinoma of the submandibular gland: a rare small round blue cell tumor

2007 ◽  
Vol 28 (2) ◽  
pp. 118-121 ◽  
Author(s):  
David M. Walters ◽  
Stewart C. Little ◽  
Richard B. Hessler ◽  
Christine G. Gourin
Keyword(s):  
Cell Carcinoma ◽  
Submandibular Gland ◽  
Small Cell Carcinoma ◽  
Small Cell ◽  
Cell Tumor ◽  
Blue Cell ◽  
Round Blue Cell Tumor

Chemotherapy of small-cell carcinoma of lung: a randomized comparison of alternating and sequential combination chemotherapy programs.

1984 ◽  
Vol 2 (11) ◽  
pp. 1192-1199 ◽  
Author(s):  
J R Daniels ◽  
L Y Chak ◽  
B I Sikic ◽  
P Lockbaum ◽  
M Kohler ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Combination Chemotherapy ◽  
Initial Treatment ◽  
Disease Free Survival ◽  
Small Cell ◽  
Limited Disease ◽  
Whole Brain Radiation ◽  
Sequential Schedule ◽  
Field Radiation

One hundred forty-seven eligible patients with small-cell carcinoma of the lung (SCCL) have been randomized to receive alternating (A) or sequential (S) combination chemotherapy. Initial treatment was with three cycles of VAM (A) or two cycles of POCC (S). VAM consists of VP16-213 200 mg/m2 intravenously (IV) day 1, Adriamycin (Adria Laboratories, Columbus, Ohio) 50 mg/m2 IV day 1, and methotrexate 30 mg/m2 IV day 1 repeated at 21-day intervals. POCC consists of cyclophosphamide 600 mg/m2 IV days 1 and 8, vincristine 1.5 mg/m2 (maximum, 2 mg) IV days 1 and 8, CCNU 60 mg/m2 po day 1, and procarbazine 100 mg/m2 po days 2 through 15. After initial treatment, all patients received whole brain radiation therapy (3,000 rad/10 fractions/2 wk). Patients with limited disease in addition received irradiation encompassing the tumor, hilar, mediastinal, and supraclavicular regions (5,000 rad/25 fractions/5 wk). After radiation, patients on arm A received POCC alternating with VAM; patients on arm S received POCC until progression when they were to be treated with VAM. The alternating arm was superior with respect to rate of complete remission (CR), median disease-free survival (MDFS), and median survival (MS). The advantage of alternating therapy was not as clearly demonstrated in the limited disease groups when interposition of involved field radiation delayed the initiation of the alternating schedule. In limited disease alone, comparing arm A with arm S, no statistically significant differences were noted. The CR rate was 42% v 54%, MDFS was 14 v 10 months, and MS was 16 v 10 months. In extensive disease, the CR rate was 44% v 20% (P = .03), MDFS was 6 v 4 months (P = .003), and MS was 10 v 7 months (P = .001). Improved treatment outcome in SCCL is achieved when combination chemotherapy regimens of similar effectiveness are administered in an alternating rather than sequential schedule.

Role of CD200 in the Detection of Nonhematologic Neoplasms by Routine Flow Cytometry Analysis

2021 ◽  
Vol 156 (Supplement_1) ◽  
pp. S7-S8
Author(s):  
Joseph Laakman ◽  
Carol Holman
Keyword(s):  
Flow Cytometry ◽  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Acinar Cell Carcinoma ◽  
Small Cell ◽  
Negative Case ◽  
Blue Cell ◽  
Poorly Differentiated ◽  
Diagnostic Work ◽  
Work Up

Abstract Objectives While flow cytometry is routinely used in the diagnostic work-up of hematolymphoid malignancies, its role in identifying non-hematolymphoid neoplasms is controversial. While a diagnosis of “non-hematolymphoid process” may be suggested by flow cytometry, typically, CD45-negative entities are not further characterized by their immunophenotypic profile. Some markers, such as CD56, have been well documented in non-hematolymphoid malignancies, such as high-grade neuroendocrine carcinomas (Stacchini, et al, 2018; Bryson et al, 2002). Other cell surface markers that are routinely studied with flow cytometry panels, such as CD200, are less well-described in the literature with regards to their presence/absence in non-hematolymphoid processes. We examined all flow cytometry cases from our institution over a 5-year period to identify trends in the immunophenotypes of non-hematolymphoid malignancies that were known to be CD45-negative and CD56-positive by flow cytometry. Methods We examined 3634 flow cytometry cases (2015-2020) and identified non-hematolymphoid cases based upon lack of CD45 expression. After excluding multiple myeloma cases from the CD45-negative entities, we were left with 19 CD45-negative cases. Chart review of these cases confirmed them as non-hematolymphoid by concurrent surgical pathology/cytopathology studies. Of these 19 cases, 2 were excluded because CD56 was not evaluated. Results Of the 17 CD45-negative/CD56-positive cases, 16 showed CD200 positivity (94%). Of these CD200-positive cases, 10 were ultimately diagnosed as small cell carcinoma (59%), 1 was diagnosed as Merkel cell carcinoma (6%), 1 was diagnosed as melanoma (6%), 1 was diagnosed as poorly-differentiated carcinoma (6%), 1 was diagnosed as Ewing-like sarcoma (6%), and 2 were unclassified further (12%). The single CD200-negative case was diagnosed as poorly-differentiated acinar cell carcinoma (6%). All cases of small cell carcinoma that were evaluated by flow cytometry showed expression of CD200 and CD56. Conclusions Our findings suggest that in CD45-negative/CD56-positive non-hematolymphoid malignancies, particularly small cell carcinoma, CD200 is frequently positive. CD200 was also found to be positive in rare cases of other non-hematolymphoid malignancies within the differential diagnosis of small round blue cell tumors. These findings indicate that CD200 may be a useful marker in suggesting the possibility of small cell carcinoma in non-hematolymphoid specimens that are evaluated by flow cytometry.

Sign in / Sign up

Export Citation Format

Share Document